NuVasive, Inc. (NASDAQ:NUVA) is reporting third quarter financial results on Thursday 29th October 2020, after market close.
According to analysts surveyed by Thomson Reuters, NUVA is expected to report 3Q20 income of $ 0.24 per share from revenue of $ 256.68 million.
For the full year, analysts anticipate top line of $ 1024.65 million, while looking forward to income of $ 0.97 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,215.00 million ~ $ 1,238.00 million, where as bottomline are predicted in a range of $ 2.55 ~ $ 2.65 per share
Click Here For More Historical Outlooks Of NuVasive, Inc.
Previous Quarter Performance
NuVasive, Inc. unfold loss for the second quarter of $ 0.40 per share, from the revenue of $ 203.61 million. The quarterly revenues decreased 30.30 percent compared with the same quarter last year. Street analysts expected NuVasive, Inc. to report loss of $ 0.47 per share on revenue of $ 175.79 million for the second quarter. The bottom line results beat street analysts by $ 0.07 or 14.89 percent, at the same time, top line results outshined analysts by $ 27.82 million or 15.83 percent.
Stock Performance
Shares of NuVasive, Inc. traded low $ -1.91 or -3.85 percent on Wednesday, reaching $ 47.71 with volume of 1.02 million shares. NuVasive, Inc. has traded high as $ 49.25 and has cracked $ 47.45 on the downward trend
According to the previous trading day, closing price of $ 47.71, representing a 73.80 % increase from the 52 week low of $ 28.55 and a 39.42 % decrease over the 52 week high of $ 81.91.
The company has a market capital of $ 2.45 billion and is part of the Healthcare sector and Medical Devices industry.
Conference Call
NuVasive, Inc. will be hosting a conference call at 1:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.nuvasive.com
NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The companys principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
